Filing Details

Accession Number:
0001214659-17-005987
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-06 18:30:13
Reporting Period:
2017-10-04
Accepted Time:
2017-10-06 18:30:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX Pharmaceutical Preparations (2834) 462693615
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1599324 Jamie Christensen C/O Mirati Therapeutics, Inc.
9393 Towne Centre Drive, Suite 200
San Diego CA 92121
Svp, Chief Science Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-10-04 4,000 $8.50 6,670 No 4 M Direct
Common Stock Disposition 2017-10-04 4,000 $14.00 2,670 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2017-10-04 4,000 $0.00 4,000 $8.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-07-16 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
  2. Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (July 17, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.